Sada Babazade

Dr. Sada Babazade

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2024 in Antimicrobial Stewardship & Healthcare Epidemiology
Verified
Journal Article
Open access
PDF file
CBCemre Boşnak
Cemre Boşnak
SFSeyda Betul Fındık
Seyda Betul Fındık
MAMuhammed Atay
Muhammed Atay
WFWard Fakhouri
Ward Fakhouri
SBSada Babazade
Sada Babazade
ÖUÖmrüm Uzun
Ömrüm Uzun
Objective: This study aims to assess the impact of hospital-specific guidelines on the optimal utilization of carbapenems and to examine their effects on patient outcomes. Design: Quasi-experimental study. Setting: Tertiary care hospital in Turkey where infectious diseases (IDs) consultation and antibiotic approval are mandatory for carbapenem use. Participants: All inpatients ≥18 years of age who received a carbapenem for at least 24 hours during the study periods were enrolled. Intervention: Hospital-specific treatment guidelines were introduced in April 2019. The control group was the year 2018, when there were no guidelines (pre-GP). The year 2020 was analyzed as the intervention period (post-GP). Results: A total of 678 patients were analyzed, 326 in the pre-GP period and 352 in the post-GP period. Following guideline implementation, there was a significant increase in appropriate carbapenem use (49.1% in pre-GP vs 71.9% in post-GP, P < .001). The duration of carbapenem use decreased significantly (P = .019). However, there was no significant change in the incidence of new infection episodes within the subsequent 30 days (27.6% in pre-GP vs 28.3% in post-GP), or in the length of hospitalization [median (25%–75%) = 28 (16–46) in pre-GP, 28 (15–47.5) in post-GP, P = .678]. Mortality rates were similar at day 7 post-GP (1.7%) compared to pre-GP (0.03%) (P = .125). Conclusions: The implementation of guidelines increased the appropriate utilization of carbapenems, without resulting in extended hospital stays or recurrent episodes. Despite an increased number of patients admitted to the ICU during the latter period, infection-related mortality rates remained comparable.

23 October 2026 in Structural Heart
Verified
Journal Article
Open access
AEAlexander Egoavil
Alexander Egoavil
BBBesir Besir
Besir Besir
CACarl Ammoury
Carl Ammoury
SBSada Babazade
Sada Babazade
WAWajeh Abuirmaileh
Wajeh Abuirmaileh
SKSamir R. Kapadia
Samir R. Kapadia

Verified
Journal Article
Open access
PDF file
CKChinmayi Kothari
Chinmayi Kothari
RCRahul Chowdhary
Rahul Chowdhary
SBSada Babazade
Sada Babazade
AEAlexander Egoavil
Alexander Egoavil
WAWajeh Abuirmaileh
Wajeh Abuirmaileh
Sunil J. WimalawansaSunil J. Wimalawansa
Sunil J. Wimalawansa
Cardiovascular calcification is an active, complex process involving osteogenic transformation, inflammation, extracellular vesicle release, and impaired mineral buffering. These changes result from mineral imbalance and reduced levels of calcification inhibitors. Vitamin K supports the γ-carboxylation of matrix Gla protein (MGP) and other mineralization inhibitors, though some calcification defenses do not depend on vitamin K. Vitamin K deficiency and warfarin therapy increase circulating dephosphorylated-uncarboxylated MGP (dp-ucMGP), which is linked to greater vascular calcification. Preclinical studies demonstrate that disruption of the vitamin K-MGP axis promotes calcification. Supplementation with vitamin K1 or K2 can reduce, prevent, or partially reverse mineralization in certain animal models. In contrast, evidence from human studies is less consistent. Observational studies have identified an association between menaquinone (vitamin K2) intake and cardiovascular outcomes, but causality has not been established. Most randomized trials have shown neutral results for aortic-valve and chronic kidney disease-associated calcification, while the VitaK-CAC and DANCODE studies reported slower progression of coronary artery calcium in selected populations with moderate or severe baseline coronary calcification. These discrepancies may be due to differences in calcification phenotypes, disease stage, vitamin K forms, dosing regimens, vitamin D status, renal function, and response to vitamin K antagonists such as warfarin. Coronary intimal, valvular, and arterial medial calcification should be regarded as phenotypically distinct entities. This review evaluates the mechanistic, preclinical, and clinical evidence linking vitamin K2 to cardiovascular calcification and highlights population groups that warrant further clinical investigation. Large, adequately powered, and phenotype-specific clinical trials are needed to determine whether appropriately dosed vitamin K2 is a safe and cost-effective intervention for slowing valvular and vascular calcification.

11 June 2026 in Structural Heart
Verified
Journal Article
Open access
BBBesir Besir
Besir Besir
CACarl Ammoury
Carl Ammoury
AEAlexander Egoavil
Alexander Egoavil
SBSada Babazade
Sada Babazade
WAWajeh Abuirmaileh
Wajeh Abuirmaileh
SKSamir R. Kapadia
Samir R. Kapadia

15 October 2026 in Structural Heart
Verified
Journal Article
Open access
AEAlexander Egoavil
Alexander Egoavil
BBBesir Besir
Besir Besir
HLHabib Layoun
Habib Layoun
CACarl Ammoury
Carl Ammoury
SBSada Babazade
Sada Babazade
SKSamir R. Kapadia
Samir R. Kapadia